In his harsh comments about the drug industry at a press conference earlier this month, President Trump declared that “pharma has a lot of lobbies and a lot of lobbyists and a lot of power.”

But how much, exactly? STAT analyzed lobbying disclosure filings updated this week to build an in-depth portrait of how the drug industry wielded its influence on the federal government in 2016.

All told, the industry’s two big trade groups spent a collective $29 million lobbying the federal government last year. And the top 15 pharma companies (by one measure) collectively spent an additional $80 million. Both figures are roughly consistent with 2015.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy